Medical News

RSS

Social defeat links past trauma to current psychosis

The feeling of social defeat may be responsible for the link between childhood trauma and psychosis, research suggests.

3 Dec 2013

Rejection sensitivity differentiates unipolar, bipolar depression

Asking about heightened rejection sensitivity during a depressive episode may help physicians to identify patients with underlying bipolarity, say researchers.

3 Dec 2013

Investigational c-Met inhibitor shows early promise in NSCLC

A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.

3 Dec 2013

Clinicians ‘nihilistic’ toward lung cancer patients

Clinicians tend to view their lung cancer patients more negatively than patients with other solid tumors, study findings indicate.

3 Dec 2013

Virginia Mason a 2013 Top Hospital by The Leapfrog Group

Virginia Mason has been named a 2013 Top Hospital by The Leapfrog Group, making this the eighth consecutive year it has earned this national recognition.

3 Dec 2013

HyGreen, HCS-Medical partner to build strategic relationships with federal healthcare markets

HyGreen, Inc., maker of the first electronic hand hygiene reminding and recording system, announced today a partnership and distribution agreement with HCS-Medical to build strategic relationships with federal healthcare markets and distribute its HyGreen Hand Hygiene System.

3 Dec 2013

U.S. physicians use CSI's Diamondback 360 Coronary OAS for coronary artery disease treatment

Cardiovascular Systems, Inc., today announced that its new Diamondback 360 Coronary Orbital Atherectomy System is being used by physicians across the country to treat coronary artery disease. This follows the company's recent PMA approval from the U.S. Food and Drug Administration to market the device as a treatment for severely calcified coronary arteries.

3 Dec 2013

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.

3 Dec 2013

Prenatal alcohol exposure impacts brain development and change behavior

Prenatal exposure to alcohol severely disrupts major features of brain development that potentially lead to increased anxiety and poor motor function, conditions typical in humans with Fetal Alcohol Spectrum Disorders, according to neuroscientists at the University of California, Riverside.

3 Dec 2013

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.

3 Dec 2013

FDA clears Cochlear Baha 4 Attract System for use in the U.S.

Cochlear Limited, the global leader in implantable hearing solutions, announced that the US Food and Drug Administration cleared the Cochlear Baha 4 Attract System for use in the United States. Cochlear is the only company to now offer patients a choice of either a magnetic or a direct bone conduction hearing solution.

3 Dec 2013

PrimeraDx gets FDA clearance for ICEPlex C. difficile Assay Kit and ICEPlex System

PrimeraDx, a molecular diagnostics company, announced today that the ICEPlex C. difficile Assay Kit and the ICEPlex System have received 510(k) clearance from the United States Food and Drug Administration.

3 Dec 2013

Dye reduction in diagnostic heart procedures: an interview with Mike McCormick, CEO Osprey Medical

Iodine based contrast media (dye) is radiopaque and is commonly used for diagnostic and interventional heart procedures. It allows physicians to see real time images of the heart vessels and treat any blockages.

3 Dec 2013

Wake Forest Baptist Medical Center renews contract for Zix Email Encryption Services

Zix Corporation, a leading provider of email data protection, announces that Wake Forest Baptist Medical Center has renewed its contract for Zix™ Email Encryption Services in a three-year agreement. A leading, fully integrated academic medical center, Wake Forest Baptist began using Zix Services in 2004 and continues to select ZixCorp based on its consistent leadership in email encryption and its dedication to ease of use.

3 Dec 2013

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

Patient Engagement Systems, a nationally recognized leader in developing technology to identify, and monitor individuals with chronic kidney disease, today introduced the Patient Engagement Systems' ESRD Prevention Program which uses proprietary technology including automated physician-patient engagement, analytics, and decision support tools to identify patients with undiagnosed chronic kidney disease and tools to monitor them in order to prevent or delay the progression to ESRD.

3 Dec 2013

First Edition: December 3, 2013

Today's headlines include coverage of the mixed reviews regarding healthcare.gov's "relaunch" as well as the White House strategy to move past the website's difficulties.

3 Dec 2013

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.

3 Dec 2013

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

3 Dec 2013

MitoQ Targeted Antioxidant Dietary Supplement now available

MitoQ Limited is excited to announce the release of their newest offering, MitoQ Targeted Antioxidant Dietary Supplement. Published studies show that the supplement, which delivers the well known antioxidant CoQ to the mitochondria (our cellular power source) better than ever before, helps repair mitochondrial dysfunction, significantly reduces oxidative damage to cells and by association supports heart, liver and brain health while assisting in the increase of energy, libido and healthy aging.

3 Dec 2013

Sound Physicians agrees to provide hospitalist services for John Peter Smith Hospital

Sound Physicians, a leading hospitalist organization focused on driving improvements in quality, satisfaction and financial performance of inpatient healthcare delivery, announced today an agreement to provide hospitalist services for John Peter Smith Hospital in Fort Worth, Texas.

3 Dec 2013

Medical News

Social defeat links past trauma to current psychosis

Rejection sensitivity differentiates unipolar, bipolar depression

Investigational c-Met inhibitor shows early promise in NSCLC

Clinicians ‘nihilistic’ toward lung cancer patients

Virginia Mason a 2013 Top Hospital by The Leapfrog Group

HyGreen, HCS-Medical partner to build strategic relationships with federal healthcare markets

U.S. physicians use CSI's Diamondback 360 Coronary OAS for coronary artery disease treatment

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

Prenatal alcohol exposure impacts brain development and change behavior

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

FDA clears Cochlear Baha 4 Attract System for use in the U.S.

PrimeraDx gets FDA clearance for ICEPlex C. difficile Assay Kit and ICEPlex System

Dye reduction in diagnostic heart procedures: an interview with Mike McCormick, CEO Osprey Medical

Wake Forest Baptist Medical Center renews contract for Zix Email Encryption Services

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

First Edition: December 3, 2013

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

MitoQ Targeted Antioxidant Dietary Supplement now available

Sound Physicians agrees to provide hospitalist services for John Peter Smith Hospital

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News